Arai, Hideki
Ueda, Shinichiro
Uchida, Kazutaka
Sakakibara, Fumihiro
Kinjo, Norito
Nezu, Mari
Morimoto, Takeshi http://orcid.org/0000-0002-6844-739X
Funding for this research was provided by:
Bristol-Myers Squibb
Japan Society for the Promotion of Science (JP21H03176)
Article History
Accepted: 23 June 2022
First Online: 19 July 2022
Change Date: 18 August 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40268-022-00401-7
Declarations
:
: Not applicable.
: The Institutional Review Boards of the University of the Ryukyus (No. 597) and all 71 participating centers approved the study protocol in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan (electronic supplementary Table). Written informed consent was replaced with the opt-out method.
: Dr. Morimoto reports lecturer's fees from Bayer, Daiichi Sankyo, Japan Lifeline, Kyocera, Mitsubishi Tanabe, Novartis, and Toray; the manuscript fees from Bristol-Myers Squibb and Kowa; served advisory boards for Asahi Kasei, Boston Scientific, Bristol-Myers Squibb, and Sanofi. Dr. Ueda reports receiving a research grant from Bristol-Myers Squibb, Chugai, Kowa, MSD, Pfizer, and Takeda, lecturer’s fee from Boehringer Ingelheim, MSD, and Taiho, and manuscript fees from Kowa. He served on an advisory board for Otsuka. Dr. Uchida reports lecturer's fees from Daiichi Sankyo. Dr. Arai, Dr. Sakakibara, Dr. Kinjo, and Dr. Nezu declare that they have no competing interests.
: Not applicable.
: TM and SU: study conception and design, and data acquisition and management. HA and TM: statistical analyses. All authors: interpretation of the data, HA and TM: drafting of the manuscript. SU, KU, FS, NK, and MN: critical revision of the manuscript. All authors: final approval of the manuscript.